Valeant Pharmaceuticals International Inc. (NYSE:VRX)‘s stock had its “sector perform” rating restated by stock analysts at RBC Capital Markets in a research note issued on Wednesday. They presently have a $47.50 target price on the specialty pharmaceutical company’s stock. RBC Capital Markets’ target price points to a potential upside of 109.34% from the company’s previous close.

Other analysts also recently issued reports about the stock. TD Securities reiterated a “hold” rating and issued a $38.00 target price on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Rodman & Renshaw reiterated a “buy” rating and issued a $90.00 target price on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Mizuho reiterated an “underperform” rating on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Wells Fargo & Co. restated a “sell” rating and set a $19.50 price target on shares of Valeant Pharmaceuticals International in a report on Sunday, July 17th. Finally, Royal Bank Of Canada cut their price target on shares of Valeant Pharmaceuticals International from $36.00 to $35.00 and set a “sector perform” rating on the stock in a report on Wednesday. Six investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $56.49.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded down 1.09% during trading on Wednesday, hitting $22.69. 9,836,039 shares of the stock were exchanged. The stock’s market cap is $7.89 billion. The stock’s 50 day moving average is $27.32 and its 200-day moving average is $26.95. Valeant Pharmaceuticals International has a 12-month low of $18.55 and a 12-month high of $179.83.

Valeant Pharmaceuticals International (NYSE:VRX) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 EPS for the quarter, missing analysts’ consensus estimates of $1.48 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 46.59% and a negative net margin of 9.29%. The business earned $2.42 billion during the quarter, compared to the consensus estimate of $2.47 billion. During the same quarter in the previous year, the firm earned $2.14 earnings per share. The firm’s revenue for the quarter was down 11.4% compared to the same quarter last year. Equities research analysts anticipate that Valeant Pharmaceuticals International will post $6.53 EPS for the current year.

In other news, Director Argeris N. Karabelas bought 4,000 shares of the company’s stock in a transaction that occurred on Thursday, August 11th. The stock was acquired at an average price of $24.65 per share, for a total transaction of $98,600.00. Following the transaction, the director now directly owns 20,726 shares of the company’s stock, valued at approximately $510,895.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 16.37% of the company’s stock.

Large investors have recently made changes to their positions in the company. Legal & General Group Plc raised its stake in shares of Valeant Pharmaceuticals International by 2.8% in the first quarter. Legal & General Group Plc now owns 1,209,137 shares of the specialty pharmaceutical company’s stock worth $31,830,000 after buying an additional 33,247 shares in the last quarter. Okumus Fund Management Ltd. raised its stake in shares of Valeant Pharmaceuticals International by 98.5% in the first quarter. Okumus Fund Management Ltd. now owns 3,722,464 shares of the specialty pharmaceutical company’s stock worth $97,901,000 after buying an additional 1,846,864 shares in the last quarter. LPL Financial LLC raised its stake in shares of Valeant Pharmaceuticals International by 65.5% in the first quarter. LPL Financial LLC now owns 91,050 shares of the specialty pharmaceutical company’s stock worth $2,616,000 after buying an additional 36,046 shares in the last quarter. Seven Eight Capital LLC bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth approximately $374,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth approximately $1,728,000. Institutional investors and hedge funds own 63.59% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.